Latest / DDReg Knowledge Capsule
Global Orphan Drug Designations: Building a Cross-Market Strategy
In this episode of the DDReg Knowledge Capsule, we explore the strategic importance of building a comprehensive, multi-market regulatory approach for rare disease treatments. While orphan drug frameworks in the US, EU, Japan, and Australia share the goal of incentivising development for niche populations, they differ significantly in their prevalence thresholds, eligibility criteria, and financial incentives.
For more details, visit our blog:
https://resource.ddregpharma.com/blogs/orphan-drug-designation-strategy/
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.